CN113398186B - Viola yedoensis makino extract and preparation method and application thereof - Google Patents
Viola yedoensis makino extract and preparation method and application thereof Download PDFInfo
- Publication number
- CN113398186B CN113398186B CN202110957291.3A CN202110957291A CN113398186B CN 113398186 B CN113398186 B CN 113398186B CN 202110957291 A CN202110957291 A CN 202110957291A CN 113398186 B CN113398186 B CN 113398186B
- Authority
- CN
- China
- Prior art keywords
- enzymolysis
- extract
- ethanol
- chinese violet
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 238000000605 extraction Methods 0.000 title claims description 20
- 244000137773 Viola philippica Species 0.000 title abstract description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 128
- 235000017352 Telosma cordata Nutrition 0.000 claims abstract description 44
- 240000006688 Telosma cordata Species 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 33
- 206010047470 viral myocarditis Diseases 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 16
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 238000001914 filtration Methods 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 11
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 10
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 27
- 230000002107 myocardial effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 10
- 230000004217 heart function Effects 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 abstract description 4
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 36
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 22
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 22
- 229940088598 enzyme Drugs 0.000 description 21
- 239000000469 ethanolic extract Substances 0.000 description 21
- 238000003756 stirring Methods 0.000 description 18
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 17
- 235000001671 coumarin Nutrition 0.000 description 16
- 150000004775 coumarins Chemical class 0.000 description 15
- 229930003935 flavonoid Natural products 0.000 description 14
- 150000002215 flavonoids Chemical class 0.000 description 14
- 235000017173 flavonoids Nutrition 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 11
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 11
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 11
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 11
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 11
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 11
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 11
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 11
- 235000009498 luteolin Nutrition 0.000 description 11
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 11
- 229940117954 naringenin Drugs 0.000 description 11
- 235000007625 naringenin Nutrition 0.000 description 11
- 235000005875 quercetin Nutrition 0.000 description 11
- 229960001285 quercetin Drugs 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 206010040047 Sepsis Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000005240 left ventricle Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 108090000145 Bacillolysin Proteins 0.000 description 5
- 108010059892 Cellulase Proteins 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- 102000035092 Neutral proteases Human genes 0.000 description 5
- 108091005507 Neutral proteases Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229940106157 cellulase Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 201000007119 infective endocarditis Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229930002875 chlorophyll Natural products 0.000 description 3
- 235000019804 chlorophyll Nutrition 0.000 description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- -1 steroid compounds Chemical class 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940063655 aluminum stearate Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001253169 Asystasia gangetica Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000709675 Coxsackievirus B3 Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Chemical class 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 229940067866 dandelion extract Drugs 0.000 description 1
- 235000020691 dandelion extract Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001845 taraxacum officinale leaf extract Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000010967 transthoracic echocardiography Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese violet extract and a preparation method and application thereof, belonging to the technical field of biological medicines. The invention uses traditional water decoction to process the Chinese violet medicinal material, combines an enzymolysis method to dissociate aglycone in an extracting solution, and then uses ethanol to enrich polar and weak polar compounds in the extracting solution, thereby laying a good material foundation for preparation. Pharmacological tests show that the viola yedoensis makino extract obtained by the method can improve the cardiac function and myocardial tissue inflammation state of mice with viral myocarditis, and the extract has a good myocardial protection effect on the viral myocarditis, so the viola yedoensis makino extract has a good value in practical application.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a Chinese violet extract and a preparation method and application thereof.
Background
The information in this background section is only for enhancement of understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art that is already known to a person of ordinary skill in the art.
The herba Violae is Violae herba Violae of ViolaceaeViolaye doensis Makino's dried whole herb has wide distribution in China, and the medicinal material resource is abundant. Viola Yedoensis Makino is bitter and pungent in flavor and cold in nature, and has the effects of clearing heat and removing toxicity, cooling blood and relieving swelling, and is also indicated for surgical diseases in compendium in essential ingredient, but ancient people always have the effects of clearing heat and removing dampness by treating jaundice and pharyngitis. The theory that the big prescription can not be abandoned easily is that the medicine is used for treating sore pyogenic infections, carbuncle, cellulitis, back, erysipelas, snake venom bite and the like. Modern pharmacological studies show that the Chinese violet has the effects of resisting bacteria, inflammation, immunity regulation, oxidation, tumors and the like, and also has broad-spectrum antiviral effect (such as Toxue and the like, the research progress of chemical components and antiviral effect of the Chinese violet, food and medicine, 3 rd stage 2020).
Herba Violae contains flavonoids, coumarins, steroids, cyclic peptide compounds, amides, organic acids, terpenes, lignans, etc.; recent studies have shown that coumarins are the main antibacterial component; in addition, researches on other components also show that different components in the Chinese violet have different pharmacological effects.
One of the main purposes of the modernization of traditional Chinese medicine is to convert the traditional Chinese medicine 'coarse, large and black' into delicate, efficient and portable dosage form by combining the modern technology. Therefore, extracting effective components or parts and removing impurities to the maximum extent are one of the subjects of the universal research of modernization of traditional Chinese medicine. In recent years, the refining research of the Chinese violet medicinal material is frequently seen, but the ethanol reflux is taken as the first step of extraction due to the limitation of the physicochemical properties of chemical components in the Chinese violet, and the purpose of the ethanol reflux is to extract and obtain flavone and coumarin components in the medicinal material. For example, chinese patents CN105770207A, CN10341749A, CN102526357A, etc. and the scientific literature available at present adopt the above methods mostly because the chemical components are easily dissolved in ethanol.
The viola philippica is a whole herb medicinal material, leaves of the viola philippica account for 80-95% of the whole herb, the chlorophyll content in leaves is huge, most of chlorophyll can be separated out into a solvent after ethanol backflow, and how to remove the chlorophyll needs to be considered in subsequent concentration and filtration steps. Meanwhile, after ethanol extraction, there is basically a step of recovering ethanol for concentration, in which a part of water-insoluble substances is precipitated, but the extraction rate is impaired. Therefore, the technology involved in the above patent requires a great cost if it is converted to a large production, and the extraction rate is not necessarily much higher.
In the traditional theory, most of the medicinal materials are decocted, ground or juiced, and the like, so that the medicinal materials can also exert better medicinal effects. According to records in Qianjin prescriptions for emergency, herba Violae is used alone for treating furuncle and pyogenic infections, the method is to take herba Violae after pounding into juice, and most of the other prescriptions are decocted with water.
As a whole herb medicine, the dosage of the philippine violet herb in the prescription is often larger, such as honeysuckle detoxification decoction, Wushen decoction and the like. Therefore, a method for treating the Chinese violet medicinal material is still needed at present, which can not only accord with the traditional Chinese medicine theory, but also better realize the refining purpose.
Most of the flavone and steroid compounds in plants exist in the form of glycosides, so that the use of enzymes to dissociate aglycones in the extraction process and then the extraction with polar solvents is proposed, so that effective components can be extracted more fully, but the use of enzymes as assistance in the extraction process has more rigorous requirements on extraction conditions (including temperature, pH value, time and the like), and how the influence of the conditions on the final extract is not evaluated by people.
Disclosure of Invention
Based on the defects of the prior art, the invention provides a Chinese violet extract and a preparation method and application thereof. The invention uses traditional water decoction to process the Chinese violet medicinal material, combines an enzymolysis method to dissociate aglycone in an extracting solution, and then uses ethanol to enrich polar and weak polar compounds in the extracting solution. In addition, animal experiments show that the Chinese violet extract prepared by the method has the effect of improving the heart function of mice with viral myocarditis, so that the Chinese violet extract has good practical application value.
In order to achieve the technical purpose, the invention relates to the following technical scheme:
in one aspect of the invention, the preparation method of the Chinese violet extract is provided, and the preparation method comprises the steps of decocting, carrying out enzymolysis and extracting the Chinese violet;
wherein in the enzymolysis step, the enzyme is any one or more of cellulase, neutral protease, papain and beta-glucosidase.
In a second aspect of the present invention, the extract of Chinese violet prepared by the above preparation method is provided. Experiments prove that the Chinese violet extract has the function of improving the heart function of mice with viral myocarditis.
Therefore, the third aspect of the invention provides the application of the Chinese violet extract in preparing medicines for treating inflammation-related diseases.
Wherein the inflammation-related disease comprises sepsis, pneumonia, hepatitis, rheumatoid arthritis, systemic lupus erythematosus, asthma, viral myocarditis, acute respiratory distress syndrome, pancreatitis, sepsis, ulcerative colitis, bronchitis, and infectious endocarditis, preferably viral myocarditis.
In a fourth aspect of the invention, a pharmaceutical composition is provided, and the active ingredients of the pharmaceutical composition comprise the Chinese violet herb extract.
Further, the pharmaceutical composition also comprises at least one pharmaceutical active ingredient or pharmaceutical carrier.
In a fifth aspect of the present invention, there is provided a method of treating an inflammation-related disorder, the method comprising: administering to the subject an effective dose of the above extract of Viola yedoensis Makino or the above pharmaceutical composition.
The inflammation-related diseases include sepsis, pneumonia, hepatitis, rheumatoid arthritis, systemic lupus erythematosus, asthma, viral myocarditis, acute respiratory distress syndrome, pancreatitis, sepsis, ulcerative colitis, bronchitis, and infectious endocarditis, preferably viral myocarditis.
The beneficial technical effects of one or more technical schemes are as follows:
the preparation method of the viola yedoensis makino extract fully considers the characteristics of traditional water decoction medicinal material treatment, simultaneously combines modern theory, utilizes enzyme to free aglycone, further refines the extract, and lays a foundation for better exerting the pharmacological action of the next preparation. The Chinese violet extract obtained by the preparation method can regulate the serum inflammatory factor level of mice with viral myocarditis, reduce the expression of myocardial tissue IGF-1, play a role in myocardial protection, and can be used as a candidate drug for antiviral myocarditis to prepare clinically acceptable drug formulations, so the Chinese violet extract has good practical application value.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this specification, are included to provide a further understanding of the invention, and are incorporated in and constitute a part of this specification, illustrate exemplary embodiments of the invention and together with the description serve to explain the invention and not to limit the invention.
FIG. 1 is a microscopic observation result of myocardial pathological tissue of a mouse model group in Experimental example 1 of the present invention.
FIG. 2 is a microscopic observation result of the myocardial pathological tissue of the control mice in Experimental example 1 of the present invention.
FIG. 3 is a microscopic observation result of the myocardial pathological tissue of the mice in the treatment group in Experimental example 1 of the present invention.
Detailed Description
It is to be understood that the following detailed description is exemplary and is intended to provide further explanation of the invention as claimed. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments in accordance with the present application. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, and it should be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof, unless the context clearly indicates otherwise.
In a typical embodiment of the invention, the preparation method of the Chinese violet extract is provided, and the preparation method comprises the steps of decocting, carrying out enzymolysis and extracting the Chinese violet;
wherein in the enzymolysis step, the enzyme is any one or more of cellulase, neutral protease, papain and beta-glucosidase.
The specific method of the decoction step comprises the following steps: soaking herba violae in water, decocting for 2-3 times, mixing decoctions, and filtering to obtain a decoction;
the amount of water added in each decoction is controlled to be 1g of herba violae medicinal material per 4-6 g of water.
The enzymolysis step specifically comprises: concentrating the decoction under reduced pressure, adding enzyme, and performing enzymolysis to obtain enzymolysis solution;
the final density of the decoction after decompression concentration is controlled to be 0.60-1.10 (80 ℃).
The amount of the added enzyme is controlled to be 1g of enzyme, the amount of the added enzyme is 80-160 g, such as 80g, 100g, 120g, 140g and 160g, the enzymolysis treatment temperature is 40-65 ℃, such as 40 ℃, 45 ℃, 50 ℃, 55 ℃, 60 ℃ and 65 ℃, the enzymolysis treatment time is controlled to be 0.5-2.5 h, such as 0.5h, 1h, 1.5h, 2h and 2.5h, the enzymolysis pH is controlled to be acidic, further controlled to be 3.0-6.5, such as pH is 3.0, 4.0, 5.0, 6.0 and 6.5, and the enzyme is beta-glucosidase. By optimizing enzymolysis conditions, the enzymolysis is more sufficient, and the active ingredients (such as aglycone and the like) of the Chinese violet medicament can be fully released.
In the extraction step, an organic solvent is selected as an extractant, ethanol is further preferably selected, and after the ethanol is added, the concentration of the ethanol in the solution is controlled to be 40-80%, such as 40%, 50%, 55%, 60%, 70%, 80%, and preferably 55%, so as to obtain an ethanol extract. The polar and weak polar compounds in the ethanol are effectively enriched by using the ethanol.
In another embodiment of the present invention, the preparation method further includes a step of concentrating and drying the prepared ethanol extract, and specifically includes: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
In another embodiment of the present invention, the viola yedoensis makino extract prepared by the above preparation method is provided. Experiments prove that the Chinese violet extract has the function of improving the heart function of mice with viral myocarditis.
Therefore, in another embodiment of the present invention, the use of the above extract of Chinese violet herb for preparing a medicament for treating inflammation-related diseases is provided.
Wherein the inflammation-related disease comprises sepsis, pneumonia, hepatitis, rheumatoid arthritis, systemic lupus erythematosus, asthma, viral myocarditis, acute respiratory distress syndrome, pancreatitis, sepsis, ulcerative colitis, bronchitis, and infectious endocarditis, preferably viral myocarditis. Experiments prove that the Chinese violet extract prepared by the invention can improve the cardiac function and myocardial tissue inflammation state of mice with viral myocarditis, and the extract has a better myocardial protection effect on the viral myocarditis.
In another embodiment of the invention, the active ingredient of the pharmaceutical composition comprises the Chinese violet herb extract.
In yet another embodiment of the present invention, the pharmaceutical composition further comprises at least one pharmaceutically active ingredient or a pharmaceutical carrier. Wherein the pharmaceutically active ingredient may be a dandelion extract.
The pharmaceutical composition containing the Chinese violet extract can be administrated in a unit dosage form. The administration dosage form can be liquid dosage form or solid dosage form. The liquid dosage forms can be true solutions, colloids, microparticles, emulsions, and suspensions. Other dosage forms such as tablet, capsule, dripping pill, aerosol, pill, powder, solution, emulsion, granule, suppository, lyophilized powder for injection, clathrate, landfill, patch, liniment, etc.
The pharmaceutical combination or pharmaceutical preparation of the present invention may further comprise a conventional carrier, wherein the pharmaceutically acceptable carrier includes but is not limited to: ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycerol, sorbates, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, beeswax, lanolin and the like. The carrier may be present in the pharmaceutical composition in an amount of from 1% by weight to 98% by weight, typically about 80% by weight. For convenience, preservatives, buffers and the like may be dissolved directly in the carrier.
Oral tablets and capsules may contain excipients such as binding agents, for example syrup, acacia, sorbitol, tragacanth, or polyvinylpyrrolidone, fillers such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, glycine, lubricants such as magnesium stearate, talc, polyethylene glycol, silica, disintegrants such as potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets may be coated by methods known in the art of pharmacy.
The oral liquid can be made into water and oil suspension, solution, emulsion, syrup, or dried product, and supplemented with water or other suitable medium before use. Such liquid preparations may contain conventional additives such as suspending agents, sorbitol, cellulose methyl ether, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gelatin, hydrogenated edible fats and oils, emulsifying agents such as lecithin, sorbitan monooleate, gum arabic; or a non-aqueous carrier (which may comprise an edible oil), such as almond oil, an oil such as glycerol, ethylene glycol, or ethanol; preservatives, e.g. methyl or propyl p-hydroxybenzoates, sorbic acid. Flavoring or coloring agents may be added if desired.
In yet another embodiment of the present invention, there is provided a method of treating a disease associated with inflammation, the method comprising: administering to the subject an effective dose of the above extract of Viola yedoensis Makino or the above pharmaceutical composition.
The inflammation-related diseases include sepsis, pneumonia, hepatitis, rheumatoid arthritis, systemic lupus erythematosus, asthma, viral myocarditis, acute respiratory distress syndrome, pancreatitis, sepsis, ulcerative colitis, bronchitis, and infectious endocarditis, preferably viral myocarditis.
The subject refers to an animal, preferably a mammal, most preferably a bovine, who has been the object of treatment, observation or experiment. By "therapeutically effective amount" is meant an amount of active compound or pharmaceutical agent, including a compound of the present invention, that elicits the biological or medical response in a tissue system, animal, or other subject sought by a researcher, veterinarian, medical doctor or other medical professional, which includes alleviation or partial alleviation of the symptoms of the disease, syndrome, condition, or disorder being treated. It will be appreciated that the optimum dosage and interval for administration of the active ingredients of the invention will be determined by the nature and external conditions, such as the form, route and site of administration and the particular mammal being treated, and that such optimum dosage may be determined by conventional techniques. It should also be recognized that the optimal course of treatment may be determined by methods known in the art.
The invention is further illustrated by the following examples, which are not to be construed as limiting the invention thereto. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The reagents and materials involved in the preparation method in the embodiment are all medicinal reagents or analytically pure or chemically pure reagents, and the reagents and materials involved in the pharmacological test are all chemically pure or biochemical reagents, which can be obtained in the market. The experimental procedures involved in pharmacological testing are well known to those skilled in the art.
Example 1 determination of the content of Flavonoids and coumarins in Viola yedoensis Makino extract
The purpose of this example is to measure the content of flavonoids and coumarins in the extract of Viola yedoensis Makino by HPLC. The specific method comprises the following steps:
(1) chromatographic conditions are as follows: octadecylsilane chemically bonded silica is used as a filler for the chromatographic column; the sample amount is 10 mul, the column temperature is 30 ℃, and the detection wavelength is 290 nm; the mobile phase A is acetonitrile; the mobile phase B is 14mmol/L ammonium acetate aqueous solution; gradient elution (0-10 min, A10-25%, 10-20min, A25-60%).
(2) Control solution: accurately weighing aesculin, aesculetin, quercetin, luteolin and naringenin respectively, placing into a volumetric flask, adding methanol to obtain mixed solutions with concentrations of 100 μ g/ml, 50 μ g/ml and 25 μ g/ml, and making into mixed reference solution.
(3) Test solution: precisely weighing 5mg of herba Violae extract powder, placing in a volumetric flask, adding methanol, ultrasonically dissolving, diluting to scale, shaking, filtering, and collecting the filtrate as sample solution.
(4) Content determination: respectively and precisely sucking the reference solution and the test solution, injecting into a liquid chromatograph, and measuring to obtain the content of flavonoids and coumarins in the herba Violae extract, wherein the flavonoids comprise quercetin, luteolin and naringenin, and the coumarins comprise aesculin and aesculetin.
Example 2 preparation of viola yedoensis makino extract:
(1) decocting: soaking herba Violae in water for 30min, decocting for 3 times (5 times of the amount of the medicinal materials per time, 1 hr, and 0.5 hr), mixing decoctions, and filtering to obtain water decoction;
(2) enzymolysis: the decoction is moderately decompressed and concentrated to the density of 0.8 (80 ℃), and beta-glucosidase is added for enzymolysis, and the enzymolysis conditions are as follows: each 1g of enzyme corresponds to 140g of medicinal materials; the enzymolysis temperature is 50 ℃, the enzymolysis time is 1 hour, the enzymolysis pH value is 4.5, and the enzymolysis liquid is obtained by stirring in due time;
(3) extraction: adding ethanol into the enzymolysis solution to make the ethanol concentration of the solution reach 55%, stirring thoroughly, standing overnight, and filtering to obtain ethanol extract;
(4) concentrating and drying: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
(5) Content determination: according to the method described in example 1, the contents of flavonoids and coumarins in the extract of Viola yedoensis Makino are determined as follows: 15.6% of aesculin, 18.5% of aesculetin, 7.6% of quercetin, 9.7% of luteolin and 4.2% of naringenin.
Example 3 preparation of viola yedoensis makino extract:
(1) decocting: soaking herba Violae in water for 30min, decocting for 3 times (5 times of the amount of the medicinal materials per time, 1 hr, and 0.5 hr), mixing decoctions, and filtering to obtain water decoction;
(2) enzymolysis: the decoction is moderately decompressed and concentrated to the density of 0.6 (80 ℃), and cellulase is added for enzymolysis, and the enzymolysis conditions are as follows: 160g of medicinal materials are added for every 1g of enzyme; the enzymolysis temperature is 65 ℃, the enzymolysis time is 0.5 hour, the enzymolysis pH value is 4, and the enzymolysis liquid is obtained by stirring in due time during the enzymolysis process;
(3) extraction: adding ethanol into the enzymolysis solution to make the ethanol concentration of the solution reach 40%, stirring thoroughly, standing overnight, and filtering to obtain ethanol extract;
(4) concentrating and drying: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
(5) Content determination: according to the method described in example 1, the contents of flavonoids and coumarins in the extract of Viola yedoensis Makino are determined as follows: aesculin 13.9%, aesculetin 16.7%, quercetin 3.3%, luteolin 5.1%, and naringenin 2.6%.
Example 4 preparation of viola yedoensis makino extract:
(1) decocting: soaking herba Violae in water for 30min, decocting for 3 times (5 times of the amount of the medicinal materials per time, 1 hr, and 0.5 hr), mixing decoctions, and filtering to obtain water decoction;
(2) enzymolysis: the decoction is moderately decompressed and concentrated to the density of 1.1 (80 ℃), neutral protease is added for enzymolysis, and the enzymolysis conditions are as follows: each 1g of enzyme corresponds to 80g of medicinal materials; the enzymolysis temperature is 40 ℃, the enzymolysis time is 2.5 hours, the enzymolysis pH value is 6, and the enzymolysis liquid is obtained by stirring in due time during the enzymolysis process;
(3) extraction: adding ethanol into the enzymolysis solution to make the ethanol concentration of the solution reach 80%, stirring thoroughly, standing overnight, and filtering to obtain ethanol extract;
(4) concentrating and drying: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
(5) Content determination: according to the method described in example 1, the contents of flavonoids and coumarins in the extract of Viola yedoensis Makino are determined as follows: 14.3 percent of aesculin, 16.4 percent of aesculetin, 4.1 percent of quercetin, 5.9 percent of luteolin and 3.3 percent of naringenin.
Example 5 preparation of extract of Viola yedoensis Makino:
(1) decocting: soaking herba Violae in water for 30min, decocting for 3 times (5 times of the amount of the medicinal materials per time, 1 hr, and 0.5 hr), mixing decoctions, and filtering to obtain water decoction;
(2) enzymolysis: the decoction is moderately decompressed and concentrated to the density of 0.7 (80 ℃), papain and beta-glucosidase (1: 2) are added for enzymolysis, and the enzymolysis conditions are as follows: every 1g of enzyme corresponds to 100g of medicinal materials; the enzymolysis temperature is 45 ℃, the enzymolysis time is 2.0 hours, the enzymolysis pH value is 5, and the enzymolysis liquid is obtained by stirring in due time during the enzymolysis process;
(3) extraction: adding ethanol into the enzymolysis solution to make the ethanol concentration of the solution reach 60%, stirring thoroughly, standing overnight, and filtering to obtain ethanol extract;
(4) concentrating and drying: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
(5) Content determination: according to the method described in example 1, the contents of flavonoids and coumarins in the extract of Viola yedoensis Makino are determined as follows: 14.6% of aesculin, 16.9% of aesculetin, 4.5% of quercetin, 5.3% of luteolin and 3.0% of naringenin.
Example 6 preparation of viola yedoensis makino extract:
(1) decocting: soaking herba Violae in water for 30min, decocting for 3 times (5 times of the amount of the medicinal materials per time, 1 hr, and 0.5 hr), mixing decoctions, and filtering to obtain water decoction;
(2) enzymolysis: the decoction is moderately decompressed and concentrated to the density of 1.08 (80 ℃), neutral protease and beta-glucosidase (1: 3) are added for enzymolysis, and the enzymolysis conditions are as follows: each 1g of enzyme corresponds to 110g of medicinal materials; the enzymolysis temperature is 60 ℃, the enzymolysis time is 1.0 hour, the enzymolysis pH value is 6.5, and the enzymolysis solution is obtained by stirring in due time during the enzymolysis process;
(3) extraction: adding ethanol into the enzymolysis solution to make the ethanol concentration of the solution reach 65%, stirring thoroughly, standing overnight, and filtering to obtain ethanol extract;
(4) concentrating and drying: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
(5) Content determination: according to the method described in example 1, the contents of flavonoids and coumarins in the extract of Viola yedoensis Makino are determined as follows: 14.2 percent of aesculin, 17.5 percent of aesculetin, 5.6 percent of quercetin, 8.3 percent of luteolin and 3.1 percent of naringenin.
Example 7 preparation of viola yedoensis makino extract:
(1) decocting: soaking herba Violae in water for 30min, decocting for 3 times (5 times of the amount of the medicinal materials per time, 1 hr, and 0.5 hr), mixing decoctions, and filtering to obtain water decoction;
(2) enzymolysis: the decoction is moderately decompressed and concentrated to the density of 1.02 (80 ℃), and beta-glucosidase is added for enzymolysis, and the enzymolysis conditions are as follows: each 1g of enzyme corresponds to 120g of medicinal materials; the enzymolysis temperature is 50 ℃, the enzymolysis time is 1 hour, the enzymolysis pH value is 4.0, and the enzymolysis solution is obtained by stirring in due time during the enzymolysis process;
(3) extraction: adding ethanol into the enzymolysis solution to make the ethanol concentration of the solution reach 50%, stirring thoroughly, standing overnight, and filtering to obtain ethanol extract;
(4) concentrating and drying: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
(5) Content determination: according to the method described in example 1, the contents of flavonoids and coumarins in the extract of Viola yedoensis Makino are determined as follows: 14.9% of aesculin, 17.3% of aesculetin, 6.8% of quercetin, 9.2% of luteolin and 3.9% of naringenin.
Example 8 preparation of viola yedoensis makino extract:
(1) decocting: soaking herba Violae in water for 30min, decocting for 3 times (5 times of the amount of the medicinal materials per time, 1 hr, and 0.5 hr), mixing decoctions, and filtering to obtain water decoction;
(2) enzymolysis: the decoction is moderately decompressed and concentrated to the density of 0.94 (80 ℃), and beta-glucosidase, cellulase and neutral protease (4: 1: 1) are added for enzymolysis, and the enzymolysis conditions are as follows: 150g of medicinal materials are added per 1g of enzyme; the enzymolysis temperature is 55 ℃, the enzymolysis time is 1.5 hours, the enzymolysis pH value is 5.5, and the enzymolysis solution is obtained by stirring in due time during the enzymolysis process;
(3) extraction: adding ethanol into the enzymolysis solution to make the ethanol concentration of the solution reach 55%, stirring thoroughly, standing overnight, and filtering to obtain ethanol extract;
(4) concentrating and drying: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
(5) Content determination: according to the method described in example 1, the contents of flavonoids and coumarins in the extract of Viola yedoensis Makino are determined as follows: 15.1% of aesculin, 17.7% of aesculetin, 5.4% of quercetin, 7.9% of luteolin and 3.6% of naringenin.
Example 9 preparation of viola yedoensis makino extract:
(1) decocting: soaking herba Violae in water for 30min, decocting for 3 times (5 times of the amount of the medicinal materials per time, 1 hr, and 0.5 hr), mixing decoctions, and filtering to obtain water decoction;
(2) enzymolysis: the decoction is moderately decompressed and concentrated to the density of 0.90 (80 ℃), and beta-glucosidase, cellulose and papain (4: 1: 2) are added for enzymolysis, and the enzymolysis conditions are as follows: each 1g of enzyme corresponds to 110g of medicinal materials; the enzymolysis temperature is 50 ℃, the enzymolysis time is 1.0 hour, the enzymolysis pH value is 5.0, and the enzymolysis solution is obtained by stirring in due time during the enzymolysis process;
(3) extraction: adding ethanol into the enzymolysis solution to make the ethanol concentration of the solution reach 65%, stirring thoroughly, standing overnight, and filtering to obtain ethanol extract;
(4) concentrating and drying: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
(5) Content determination: according to the method described in example 1, the contents of flavonoids and coumarins in the extract of Viola yedoensis Makino are determined as follows: 14.6 percent of aesculin, 17.3 percent of aesculetin, 4.7 percent of quercetin, 6.2 percent of luteolin and 2.8 percent of naringenin.
Comparative example 1 preparation of extract of viola yedoensis makino:
this comparative example refers to the technique disclosed in CN 102462701A.
(1) Decocting: soaking herba Violae in water for 30min, decocting for 3 times (5 times of the amount of the medicinal materials per time, 1 hr, and 0.5 hr), mixing decoctions, and filtering to obtain water decoction;
(2) enzymolysis: the decoction is moderately decompressed and concentrated to the density of 1.04 (80 ℃), cellulase is added, and the enzymolysis conditions are as follows: the amount of the added enzyme is 0.8 percent of the weight of the water decoction concentrated solution; the enzymolysis temperature is 50 ℃, the enzymolysis time is 2 hours, the enzymolysis pH value is 4, and the enzymolysis liquid is obtained by stirring in due time during the enzymolysis process;
(3) extraction: adding ethanol into the enzymolysis solution to make the ethanol concentration of the solution reach 55%, stirring thoroughly, standing overnight, and filtering to obtain ethanol extract;
(4) concentrating and drying: recovering ethanol from the ethanol extract to obtain extract, and drying the extract to obtain the Chinese violet extract.
(5) Content determination: according to the method described in example 1, the contents of flavonoids and coumarins in the extract of Viola yedoensis Makino are determined as follows: aesculin 10.7%, aesculetin 12.5%, quercetin 1.8%, luteolin 2.6%, and naringenin 0.6%.
Experimental example 1
Experiment for influence of herba Violae extract on mice with viral myocarditis
The present example discusses the effects of Viola yedoensis Makino extract on viral myocarditis model mouse mortality, serum creatine kinase isoenzyme (CK-MB), Lactate Dehydrogenase (LDH), aspartate Aminotransferase (AST), inflammatory factors (IL-6, IL-10, TNF-alpha), and cardiomyopathy, to initially evaluate the effect of Viola yedoensis Makino extract on viral myocarditis. The method comprises the following specific steps:
(1) preparing a model: 60 BALC/c mice were selected and randomly divided into model group (20), treatment group (20), and control group (20) according to body weight.
Wherein, each abdominal cavity of the model group and the treatment group of mice is injected with 0.1ml of CNB3 virus solution containing Coxsackie virus B3 (CVB 3) 100TTCID50/0.1ml, and the injection is continuously performed for 3 times to establish a mouse viral myocarditis model.
The control group was injected with an equal amount of physiological saline at the same time.
(2) The preparation of the medicine comprises the following steps: a proper amount of the Chinese violet herb extract obtained in the best embodiment of the embodiment 2 is taken and added with distilled water to be fully stirred into suspension for use when in use.
(3) Administration: after the first injection of the virus solution, the intragastric administration is started for 2 h. Wherein the treatment group is administered with 6g/kg body weight of herba Violae extract; the model group and the control group were simultaneously administered an equal volume of distilled water for intragastric administration. The administration is 1 time daily, and 14 days are continuously administered.
(4) And (4) daily observation: general condition and mortality
(5) And (3) determining the heart function of the mouse: mice were anesthetized by intraperitoneal injection of chloral hydrate, depilated with a topical depilatory, and subjected to transthoracic echocardiography using a small animal ultrasound system. Analyzing the structure and function of the left ventricle by adopting the long axis and short axis sections beside the sternum, displaying the inner diameter (LVEDD) of the left ventricle at the end diastole, the thickness (LVPWs) of the posterior wall of the left ventricle and the thickness (LVAWs) of the anterior wall of the left ventricle under the M mode, and calculating the left ventricle Ejection Fraction (EF) and the left ventricle shortening rate (FS).
(6) Serum myocardial enzyme and inflammatory factor assay: after the last administration, fasting and water deprivation are carried out for 12h, weighing is carried out, the eye artery is taken blood, centrifugation is carried out for 6min at 4000r/min, supernatant fluid is taken, and the CK-MB, AST and LDH activities and the IL-6, IL-10 and TNF-alpha contents in the serum are measured by an ELISA method.
(7) Myocardial histopathological changes: the heart of a mouse is separated after blood is taken, the heart is fixed by 4% paraformaldehyde, dehydrated, embedded by paraffin, sliced conventionally, stained by HE, and the pathological change of the myocardium is observed under a microscope.
(8) As a result:
general status, death status of mice:
the control group mice had normal eating, activity and the like during the experiment, hair color and luster, sensitive response and normal weight, and the mice did not die during the experiment;
the mice in the model group have reduced food intake and activity, shrunken hair, lusterless hair, slow response to stimulation, emaciation and 8 deaths during the experiment (mortality rate is 40%);
the treated mice generally showed a significant improvement over the model group, with 2 deaths (mortality 10%) during the experiment.
The differences were statistically significant (P <0.05) when the mortality of 3 groups of mice was compared.
② the mouse heart function test result: see Table 1
Note: p <0.05, compared to control group; p <0.05, compared to model groups
As can be seen from the above table,
the EF and FS of the model group mice are obviously reduced compared with the control group (P is less than 0.05), and the heart function is effectively improved after the model group mice are treated by the viola yedoensis makino extract (P is less than 0.05).
Thirdly, the detection result of the myocardial enzyme level in the serum: see Table 2
Note: p <0.05, compared to control group; p <0.05, compared to model groups
As can be seen from the above table, the serum CK-MB, AST and LDH levels of the model group mice are obviously increased compared with the control group (P < 0.05); compared with the model group, the serum CK-MB, AST and LDH levels of the mice in the treatment group are obviously reduced, and the difference has statistical significance (P < 0.05).
Fourthly, the detection result of the mouse serum inflammatory factor: see Table 3
Note: p <0.05, compared to control group; p <0.05, compared to model groups
As can be seen from the above table, compared with the control group, the serum IL-6 and TNF-alpha levels of the model group mice are obviously increased, and the IL-10 content is obviously reduced (P < 0.05); compared with the model group, the serum IL-6 and TNF-alpha level of the mice in the treatment group is obviously reduced, the IL-10 content is obviously increased, and the difference has statistical significance (P < 0.05).
The histopathological changes of the myocardium are detailed in figures 1-3.
The analysis of the attached figure shows that the myocardial cells of the control group mice are arranged regularly, and the proliferation of interstitial fibers and inflammatory cells is not seen; the mouse model group has the advantages that the mouse model group has the symptoms of myocardial cell enlargement, myocardial fiber arrangement disorder and myocardial interstitial edema, and a large amount of inflammatory cell infiltration and multifocal necrosis are seen; the pathological lesion degree of the mice in the treatment group is improved compared with that of the mice in the model group.
It should be noted that the above examples are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to the examples given, those skilled in the art can modify the technical solution of the present invention as needed or equivalent substitutions without departing from the spirit and scope of the technical solution of the present invention.
Claims (5)
1. The application of the Chinese violet extract in preparing the medicament for treating viral myocarditis is characterized in that the preparation method of the Chinese violet extract comprises the steps of decocting, carrying out enzymolysis and extracting the Chinese violet;
wherein in the enzymolysis step, the used enzyme is beta-glucosidase;
the enzymolysis step specifically comprises: concentrating the decoction under reduced pressure, adding enzyme, and performing enzymolysis to obtain enzymolysis solution; the final density of the decoction after reduced pressure concentration is controlled to be 0.60-1.10, 80 ℃; the amount of the added enzyme is controlled to be 80-160 g corresponding to 1g of the enzyme to the Chinese violet medicinal material, the enzymolysis treatment time is controlled to be 0.5-2.5 h, and the enzymolysis pH is controlled to be 3.0-6.5;
in the extraction step, an extracting agent selects an organic solvent;
the organic solvent is ethanol, and after the ethanol is added, the concentration of the ethanol in the solution is controlled to be 40-80%.
2. The use of claim 1, wherein said decocting step is carried out by a method comprising: soaking herba violae in water, decocting for 2-3 times, mixing decoctions, and filtering to obtain a decoction;
the amount of water added in each decoction is controlled to be 1g of herba violae medicinal material per 4-6 g of water.
3. The use of claim 1, wherein the preparation method further comprises concentrating and drying the prepared extract.
4. The use of claim 1, wherein the medicament is a pharmaceutical composition.
5. The use of claim 4, wherein the pharmaceutical composition further comprises at least one pharmaceutically active ingredient or a pharmaceutical carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110957291.3A CN113398186B (en) | 2021-08-20 | 2021-08-20 | Viola yedoensis makino extract and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110957291.3A CN113398186B (en) | 2021-08-20 | 2021-08-20 | Viola yedoensis makino extract and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113398186A CN113398186A (en) | 2021-09-17 |
CN113398186B true CN113398186B (en) | 2021-11-02 |
Family
ID=77689040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110957291.3A Active CN113398186B (en) | 2021-08-20 | 2021-08-20 | Viola yedoensis makino extract and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113398186B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102356908A (en) * | 2011-09-08 | 2012-02-22 | 董爱文 | Herba violae beverage and preparation method thereof |
CN102462701A (en) * | 2010-11-08 | 2012-05-23 | 中国中医科学院西苑医院 | Enzyme method for refining Chinese medicine extract |
CN107779483A (en) * | 2017-10-16 | 2018-03-09 | 铜仁职业技术学院 | A kind of enzyme extracting method and its assay based on response phase method Chinese violet apiolin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105902695B (en) * | 2016-05-24 | 2020-06-19 | 河北天元药业有限公司 | Novel method for preparing Shuangding injection |
CN112386655A (en) * | 2019-08-14 | 2021-02-23 | 百岳特生物技术(上海)有限公司 | Use of phalaenopsis amabilis extract for preparing composition for resisting saccharification and improving skin appearance |
-
2021
- 2021-08-20 CN CN202110957291.3A patent/CN113398186B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102462701A (en) * | 2010-11-08 | 2012-05-23 | 中国中医科学院西苑医院 | Enzyme method for refining Chinese medicine extract |
CN102356908A (en) * | 2011-09-08 | 2012-02-22 | 董爱文 | Herba violae beverage and preparation method thereof |
CN107779483A (en) * | 2017-10-16 | 2018-03-09 | 铜仁职业技术学院 | A kind of enzyme extracting method and its assay based on response phase method Chinese violet apiolin |
Non-Patent Citations (1)
Title |
---|
5种中药提取物体外抗病毒药效学研究;杨洁等;《军医进修学院学报》;20071031;第28卷(第5期);第375页摘要及正文第1-4段,第376页表1,讨论部分第1-3段 * |
Also Published As
Publication number | Publication date |
---|---|
CN113398186A (en) | 2021-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105250366B (en) | Dracocephalum moldavica extract and preparation method and application thereof | |
CN104435034B (en) | A kind of arasaponin and preparation method thereof | |
EP1013278B1 (en) | The extract of pine needle and the use thereof | |
JP2002538214A (en) | Pharmaceutical composition for treating cardiovascular disease and method for producing the same | |
CN103342726B (en) | The preparation method of a kind of blood sugar lowering camellia flavonoid and application thereof | |
CN101095720B (en) | Method for preparing total salvianolic acid and the application in the preventing and treating of diabetes and the complication thereof | |
CN107412430A (en) | A kind of radix scrophulariae water extract and its application | |
CN102309542B (en) | Orthosiphon n-butanol fraction medicine for treating chronic nephritis and preparation method thereof | |
CN101143157A (en) | Tyrosol and tyrosol bypass salidroside plant extraction and preparation and use thereof | |
CN113398186B (en) | Viola yedoensis makino extract and preparation method and application thereof | |
CN100496527C (en) | Preparation method and application of injection containing Erigeron breviscapus | |
CN1698717B (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
CN101759672A (en) | Salvianolic acid B in radix salviae miltiorrhizae | |
CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
CN100509009C (en) | A Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and ischemic apoplexy, and its preparation method | |
CN101974011B (en) | New compound methyl brevicate with medical activity | |
CN101428050A (en) | Active composition for treating thrombus, cardio-cerebrovascular system diseases | |
CN1068790C (en) | Medicinal composition containing total saponin extracted from stem and leaves of American ginseng | |
CN101974012B (en) | Novel compound ethyl brevicate with pharmaceutical activity | |
CN1468860A (en) | Manyprickle acanthopanax general saponin extractive and its medicinal composition | |
CN101974010B (en) | New compound erigeron breviscapus acid with officinal activity | |
CN108743654B (en) | Traditional Chinese medicine composition for treating ischemic heart disease and preparation method and application thereof | |
CN105535923A (en) | Leech small peptide effective part composition for treating kidney diseases and cardiovascular diseases | |
CN116270716A (en) | Polysaccharide extract of aconitum plant, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |